Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CCR5 | P51681 | 5/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21980424 | 0.94 | CCR5 (0.32) | MAPK1CCR5ATMTDP1MEN1 | |
| SCHEMBL21980448 | 0.89 | MAPK1 (0.36) | MAPK1CCR5ATMTDP1OPRM1 | |
| SCHEMBL20557769 | 0.87 | MEN1 (0.31) | MEN1KMT2A | |
| SCHEMBL20557821 | 0.84 | MEN1 (0.33) | MAPK1CCR5ATMMEN1KMT2A | |
| SCHEMBL20558005 | 0.80 | KMT2A (0.34) | MAPK1CCR5ATMTDP1MEN1 | |
| SCHEMBL21980428 | 0.79 | CCR5 (0.36) | MAPK1CCR5ATMTDP1MAPT | |
| SCHEMBL20558166 | 0.77 | — | — | |
| SCHEMBL24141866 | 0.70 | MAPK1 (0.45) | MAPK1CCR5ATMTDP1MEN1 | |
| SCHEMBL22030711 | 0.66 | — | — | |
| SCHEMBL30586123 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11046694-B2 | Compounds and methods for treating bacterial infections | ENTASIS THERAPEUTICS, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-20200165251-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | ENTASIS THERAPEUTICS, INC. | 2020-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11046694-B2 | Compounds and methods for treating bacterial infections | MRPL21, CFTR, C5 | MAPK1 946/4885CCR5 313/4885ATM 2836/4885 |
| US-20200165251-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | MRPL21, CFTR, C5 | MAPK1 946/4885CCR5 313/4885ATM 2836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.